All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
On June 29, 2023, the AML Hub hosted a discussion on “What time is the right time for transplantation?”, chaired by Selina Luger, with contributions from Steering Committee members Gert Ossenkoppele, Jeffrey Lancet, Yasushi Miyazaki, Eduardo Rego, Roland Walter, and Jorge Sierra.
What time is the right time for transplantation?
Using a case of a patient with primary refractory acute myeloid leukemia (AML), Luger discusses the options of immediate allogeneic stem cell transplantation or after achievement of remission with salvage chemotherapy. Luger then highlights the phase III ASAP trial (previously covered by the AML Hub), the Pre-MEASURE trial (previously covered by the AML Hub), and also describes a study that found allogeneic stem cell transplantation outcomes were associated with high-sensitivity detection of FLT3-internal tandem duplication measurable residual disease.
The group discusses the results of these studies, including the differences in patient populations, optimal timing of transplantation, the impact of pretransplant measurable residual disease, and whether or not salvage chemotherapy is beneficial for these patients. They also raise the importance of identifying donors for potential transplantation as early as possible.
Optimizing transplant outcomes in patients allografted for AML
During the AML Hub Steering Committee meeting held on May 17, 2023, Charles Craddock chaired a discussion on optimizing transplant outcomes in patients allografted for AML, with...
ASAP: Conditioning vs induction + allo-HSCT in R/R AML
We summarize key findings from the ASAP trial comparing sequential conditioning prior to allo-HSCT vs salvage chemotherapy followed by allo-HSCT in patients with poor response to first induction...
Subscribe to get the best content related to AML delivered to your inbox